在标准质母细胞瘤治疗中整合和优化tonabersat:一项临床前研究
Velislava Zoteva1, Valerie De Meulenaere1, Christian Vanhove2
1Department of Radiology, Ghent University, Ghent, Belgium.
PloS one
|March 15, 2024
概括
托纳伯萨特 (Tonabersat) 显示出作为质母细胞瘤 (GB) 的辅助疗法的前景,在与标准放射治疗和temozolomide (TMZ) 化疗相结合时延长存活时间. 在临床前模型中,每天在治疗前和治疗后服用tonabersat,一种连xin 43 (Cx43) 抑制剂,改善了治疗结果.
科学领域:
- 神经瘤学神经瘤学
- 癌症治疗方法 癌症治疗方法
- 药理学 药理学是指药理学的学科.
背景情况:
- 质母细胞瘤 (GB) 是一种具有不良预后的侵袭性脑瘤.
- 由连素43 (Cx43) 介导的瘤微管驱动着质瘤的进展和治疗耐药性.
- 准Cx43是GB的潜在治疗策略.
研究的目的:
- 为了评估tonabersat的辅助潜力,一个Cx43抑制剂,结合标准的GB护理.
- 调查tonabersat的最佳服药时间表,以最大限度地提高其治疗窗口.
- 在临床前的GB模型中评估tonabersat对瘤生长,存活率和治疗反应的影响.
主要方法:
- 使用了F98 Fischer老鼠模型用于质母细胞瘤.
- 施用分成型放射治疗和泰莫索洛米德 (TMZ) 化疗.
- 在放射治疗之前和之后,与标准护理相结合,每天进行调研.
- 使用CE T1-wMRI和组织学分析评估瘤生长,存活率和治疗反应.
主要成果:
- 托纳伯萨特与标准护理相结合,显著延长了患有质母细胞瘤的老鼠的存活时间.
- 每天托纳伯萨特的使用,无论是在放射治疗之前还是之后,都最大限度地提高了生存效益.
- 初步发现表明,tonabersat可能会降低瘤的侵入性.
结论:
- 托纳伯萨特显示出作为质母细胞瘤辅助疗法的显著潜力.
- 托纳伯萨特的最佳每日给药时间表可以提高生存结果.
- 在偏头痛的临床试验中,tonabersat的确定的安全性概况为进一步的质母细胞瘤研究提供了坚实的基础.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...